Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

British Ebola nurse recovers again, leaves specialist hospital unit

Published 12/11/2015, 10:58
Updated 12/11/2015, 11:00
© Reuters. Pauline Cafferkey smiles alongside Doctor Michael Jacobs and Senior Matron Breda Athan at the Royal Free Hospital in London

LONDON (Reuters) - A Scottish nurse who contracted and recovered from Ebola, but then suffered life-threatening complications from the virus persisting in her brain, has recovered enough to be transferred to a hospital near her home, doctors said on Thursday.

Medics at a specialist unit at the Royal Free Hospital in London, where Pauline Cafferkey was readmitted in October, said she was no longer infectious and had been discharged from there and admitted to a hospital in Glasgow, Scotland.

"Her condition is stable," the London hospital said in a statement.

Cafferkey, 39, contracted Ebola in December 2014 when she was working in a treatment facility in Sierra Leone at the height of an epidemic of the disease which swept through three countries in West Africa.

Cafferkey initially recovered from the Ebola haemorrhagic fever and was sent home in January.

But in October she fell ill again and doctors found the virus was persisting in tissues in her brain. They later said she had developed meningitis cause by the Ebola virus - the first known such case.

Doctors said in October that Cafferkey was being treated with an experimental antiviral drug known as GS5734 being developed by the U.S. drugmaker Gilead Sciences (O:GILD). They gave no update on Thursday about whether they thought the drug had made a difference.

Latest data from the World Health Organization on the West Africa Ebola outbreak show the virus has killed some 11,300 of the more than 28,500 people it has infected since December 2013. Sierra Leone was declared free of Ebola on November 7.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.